Transmission-Blocking Antigens Show Low Variation, Making Them a Reliable Vaccine Target Across Countries

A key challenge in developing a malaria vaccine is choosing which stage to target. Transcript A key challenge in developing a malaria vaccine is choosing which stage of the infection to target. You can target the parasite when it enters the body, multiplies in the liver and the blood, or is in the sexual stage, preparing to be picked up by a mosquito. Along with selecting the right vaccine target, it's also important to consider how these targets naturally vary in the population. To identify the optimal target, researchers examined the genetic and structural variation of ten antigens in over 1,000 samples of malaria parasites from six African countries. Interestingly, antigens involved in human infection showed the most genetic and structural variation across countries. Transmission-blocking antigens—ones that induce antibodies in humans that disrupt the parasite's development in the mosquito, thus preventing further transmission —were more conserved across regions. This makes transmission-blocking antigens excellent targets as standalone or multi-stage vaccines to prevent onward transmission to other people. Source Diversity and selection analyses identify transmission-blocking antigens as the optimal solution. About The Podcast The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.